Adaptive Biotechnologies Corporation — Q1 2023 Form 10-Q
Business context and period. Commercial-stage immune medicine company reporting the three months ended March 31, 2023, compared with Q1 2022. Its offerings include clonoSEQ minimal residual disease (MRD) testing, immunoSEQ research services and drug-discovery collaborations, including Genentech.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Revenue | $37.6 million | $38.6 million |
| Gross profit / gross margin | $19.0 million / 50.4% | $25.4 million / 65.8% |
| Operating loss | $57.2 million | $63.1 million |
| Net loss attributable to Adaptive | $57.7 million; $0.40 per share | $62.7 million; $0.44 per share |
| Adjusted EBITDA (non-GAAP) | $(37.1) million | $(43.1) million |
| Cash used in operating activities | $59.2 million | $64.5 million |
At March 31, 2023, cash and cash equivalents were $94.6 million and short-term marketable securities were $346.1 million, totaling $440.7 million. Total current assets were $501.3 million versus current liabilities of $90.1 million. The company reported total liabilities of $367.5 million and shareholders’ equity of $424.0 million. It had a $127.0 million revenue interest liability, accounted for as long-term debt, with a reported effective interest rate of 11.4%; operating lease liabilities totaled $105.8 million.
Material changes versus Q1 2022
- Total revenue declined 3%. Immune Medicine revenue fell 22% to $16.2 million, largely reflecting lower collaboration revenue, while MRD revenue rose 20% to $21.4 million.
- MRD service revenue increased 45%; clonoSEQ tests delivered rose 57% to 12,079. Q1 2022 included $3.0 million of regulatory milestone revenue, with none recognized in Q1 2023.
- Cost of revenue increased 42% to $18.7 million, reducing gross margin to 50.4% from 65.8%. The filing attributes the increase primarily to greater production-lab use for revenue samples, laboratory consolidation overhead, and assay and sample mix.
- Research and development decreased 14% to $32.6 million; sales and marketing decreased 15% to $22.3 million; general and administrative decreased 14% to $20.8 million. Management cited lower development investment and lower personnel, marketing, facility and consulting costs among the drivers.
- Operating cash use improved by $5.3 million year over year. Cash, cash equivalents and marketable securities declined from $498.2 million at December 31, 2022 to $440.7 million at March 31, 2023.
Outlook, commentary and risks
- Management expects existing cash, cash equivalents and marketable securities to fund operating expenses and capital requirements for at least the next 12 months. It expects revenue to grow over the long term, while acknowledging near-term variability. No specific full-year revenue or earnings guidance is provided in the filing.
- Management plans to fund research and development, platform and drug-discovery work, commercial activities and laboratory streamlining. It expects moderate near-term decreases in R&D expenses and moderate near-term increases in sales and marketing expenses.
- Management deferred further T-Detect commercialization until stronger evidence across multiple disease states supports physician adoption and a clear reimbursement path.
- Under its OrbiMed revenue interest purchase agreement, the company received $125.0 million at closing in 2022 and may request up to another $125.0 million by September 2025, subject to conditions. Repayments are based on a percentage of GAAP revenue.
- The company could receive up to $404.5 million in additional MRD milestone payments if customers’ therapies obtain specified regulatory approvals; these payments are contingent and were not included in recognized revenue at quarter-end. The Genentech collaboration also includes substantial contingent milestone and royalty opportunities.
- Genentech and Roche represented 26.6% of Q1 revenue. The filing highlights risks around commercial adoption, development and regulatory outcomes, collaboration performance, customer decisions and estimates of future revenue. It reports no material change to previously disclosed risk factors, no material legal proceedings, and effective disclosure controls as of March 31, 2023.
Important facts for investors to verify
- Whether clonoSEQ test growth and MRD service revenue continue, and whether the higher cost of revenue and lower gross margin improve.
- How collaboration revenue evolves, particularly Genentech-related revenue and the timing and probability of contingent milestones.
- Cash-burn trends and the assumptions supporting management’s statement that liquidity covers at least the next 12 months.
- The economic terms and future revenue-payment burden of the OrbiMed agreement, including any additional funding draw and the reported 11.4% effective interest rate.
- Whether T-Detect commercialization resumes and whether the company achieves adoption and reimbursement for its products.